Moomoo AIのまとめ
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
2024年2月15日、がん免疫療法の臨床段階の会社であるコンピュジェンは、2024年3月1日より、新しいCMOとしてMichelle Mahler博士を任命したことを発表しました。Mahler博士は2023年10月にコンピュジェンの臨床開発の副社長として入社し、その後、他のチャンスを追求するために会社を離れるHenry Adewoye博士の後任となります。Mahler博士は、1 E therapeutics Ltd.やAummune Therapeutics Ltd.などのバイオテクノロジーや医薬品会社での以前の役割から広範な経験を持ち、Gilead Sciencesとのパートナーシップで行わ...すべて展開
2024年2月15日、がん免疫療法の臨床段階の会社であるコンピュジェンは、2024年3月1日より、新しいCMOとしてMichelle Mahler博士を任命したことを発表しました。Mahler博士は2023年10月にコンピュジェンの臨床開発の副社長として入社し、その後、他のチャンスを追求するために会社を離れるHenry Adewoye博士の後任となります。Mahler博士は、1 E therapeutics Ltd.やAummune Therapeutics Ltd.などのバイオテクノロジーや医薬品会社での以前の役割から広範な経験を持ち、Gilead Sciencesとのパートナーシップで行われたCOM503 Phase 1の研究の準備に不可欠な役割を果たし、ongoing triple combination studiesでも重要な役割を果たしています。CompugenのCEOであるAnat Cohen-Dayag博士は、Adewoye博士が会社を臨床段階に移行させ、臨床および規制戦略を進めるために貢献したことに感謝の意を表明しています。Compugenは、計算対象発見で知られており、COM701やCOM902などのがん免疫療法を開発し、アストラゼネカとのパートナーシッププログラムであるrilvegostomigをPhase 3の開発中に持っています。
役に立った
役に立たない